Zentalis Pharmaceuticals Inc (NAS:ZNTL)
$ 3.83 (0%) Market Cap: 362.59 Mil Enterprise Value: 221.54 Mil PE Ratio: 0 PB Ratio: 1.91 GF Score: 32/100

Zentalis Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript

May 26, 2026 / 02:00PM GMT
Release Date Price: $3.96 (-2.46%)
Tyler Van Buren
TD Cowen - Analyst

Everyone had a great long weekend. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining TD Cowen's Seventh Oncology Summit.

For our next session, we have a Q&A with Zentalis, and it's my pleasure to introduce Julie Eastland, the CEO and President of Zentalis, and Ingmar Bruns, the Chief Medical Officer. Julie and Ingmar, it's a privilege to have you both here. Thank you for joining me.

Julie Eastland
Zentalis Pharmaceuticals Inc - President, Chief Executive Officer, Director

Thanks, Tyler, we always appreciate it.

Tyler Van Buren
TD Cowen - Analyst

Of course. So before we get started with the discussion, for those of you in the audience, feel free to email me questions at [email protected]. You can also use cowen.com, but again, that's first.last, and we'll do our best to get them asked before the end of the discussion.

Also, as you all may know, our favorite season, which is Extel voting season, kicks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot